Increased propensity for calcium phosphate kidney stones with topiramate use
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Topiramate (TPM) is a neuromodulatory agent that was initially approved as an antiepileptic drug and is increasingly used in the treatment of a number of neurological and metabolic disorders. Among its various pharmacological actions, TPM has been shown to inhibit the activity of specific carbonic anhydrase enzymes in the kidney. This action is associated with the development of metabolic acidosis, hypocitraturia, hypercalciuria and elevated urine pH, leading to an increased risk of kidney stone disease. Despite the cautionary note in the package insert of TPM, the extent of these complications has not been fully explored. Few prescribing physicians are aware of these complications, underscoring the need for improved surveillance. Because the drug is among the most frequently prescribed agents in the US, more controlled studies are required to determine the prevalence of kidney stone disease among TPM users, and the optimal approach to prevent and treat nephrolithiasis in these individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Bray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344
Biochemical and stone-risk profiles with topiramate treatment
Welch, B. J., Graybeal, D., Moe, O. W., Maalouf, N. M., & Sakhaee, K. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.07.003 · Cited by 126 · cited 4×
“Three months of TPM treatment caused significant metabolic acidosis, increased urinary pH, significantly increased urinary bicarbonate excretion and significantly increased urinary saturation of calcium phosphate [27] .”
BackgroundResultSelf-citationRosenstock, J., Hollander, P., Gadde, K. M., Sun, X., Strauss, R., Leung, A., & for the OBD-202 Study Group (2007) · Diabetes Care · doi:10.2337/dc06-2001 · Cited by 85
Cited by
Renal Vulnerability to Drug Toxicity
Perazella, M. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02050309 · Cited by 403
Pharmacology behind Common Drug Nephrotoxicities
Perazella, M. A. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00150118 · Cited by 270
Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment
Daudon, M., Frochot, V., Bazin, D., & Jungers, P. (2018) · Drugs · doi:10.1007/s40265-017-0853-7 · Cited by 191
Bays, H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.125 · Cited by 66
The effect of topiramate and lamotrigine on rat bone mass, structure and metabolism
Simko, J., Fekete, S., Gradosova, I., Malakova, J., Zivna, H., Valis, M., Palicka, V., & Zivny, P. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.02.032 · Cited by 16
“Inhibition of carbonic anhydrase is the cause of metabolic acidosis in a large number of both children and adults medicated with TPM [19].”
Background
Metadata
- Authors
- Vega, D., Maalouf, N. M., & Sakhaee, K.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2007-09
- Volume
- 6
- Issue
- 5
- Pages
- 547-557
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2068175549
- Cited by
- 59
- References
- 4
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased propensity for calcium phosphate kidney stones with topiramate use. https://app.cochat.ai/papers/10.1517/14740338.6.5.547
- The paper
- Vega, D., Maalouf, N. M., & Sakhaee, K. (2007). Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.6.5.547
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.